HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Abstract
Incorporation of novel agents has resulted in an improved response rate and reduced side effects in multiple myeloma. This has prompted combining novel agents in induction chemotherapy in patients with newly diagnosed multiple myeloma. Our patients received 2 cycles of vincristine, adriamycin, dexamethasone (VAD) and then 2 cycles of bortezomib, thalidomide, dexamethasone (VTD) chemotherapy as an induction treatment. Subsequently, autologous stem cell transplantation was performed, and bortezomib was administered as a consolidation therapy. Seventy-one patients were enrolled, and 65 were evaluable for response. After 2 cycles of VAD, the overall response rate was 69%. After VTD, the response rate improved to 97% with a complete response (CR) and near CR rate of 27%. Importantly, patients with cytogenetics, having poor prognostic features, all responded after VTD. Autologous stem cells were successfully collected in all 58 patients with a median CD34+ cell count of 7.12 × 10(6)/kg (range, 1.94-44.7 × 10(6)/kg), except in 1 patient (2%). After ASCT, 36 patients completed bortezomib maintenance with a combined CR and near CR rate approaching 75%. Median time to response was rapid (1.6 months). With a median follow-up duration of 52.7 months, the median TTP was 29.4 months and median OS was not reached. Toxicities proved manageable. In conclusion, sequential VAD and VTD induction therapy in patients with newly diagnosed multiple myeloma was active with manageable toxicity and excellent stem cell yields. The incorporation of bortezomib as a consolidation therapy improved the clinical outcome with the expense of rather frequent development of peripheral neuropathy.
AuthorsHye Jin Kim, Sung-Soo Yoon, Dong Soon Lee, Sang Kyun Sohn, Hyeon Seok Eom, Jung Lim Lee, Joo Seup Chung, Kihyun Kim, Cheolwon Suh, Jong Ho Won, Jin Seok Kim, Joon Seong Park, Hye Jin Kang, Chu Myong Seong, Cheol Soo Kim, Sang Jae Lee, Jae Hoon Lee
JournalAnnals of hematology (Ann Hematol) Vol. 91 Issue 2 Pg. 249-56 (Feb 2012) ISSN: 1432-0584 [Electronic] Germany
PMID21789621 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Vincristine
  • Bortezomib
  • Dexamethasone
  • Doxorubicin
Topics
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Boronic Acids (therapeutic use)
  • Bortezomib
  • Dexamethasone (therapeutic use)
  • Disease-Free Survival
  • Doxorubicin (therapeutic use)
  • Female
  • Humans
  • Induction Chemotherapy
  • Male
  • Middle Aged
  • Multiple Myeloma (drug therapy, physiopathology, surgery)
  • Pyrazines (therapeutic use)
  • Stem Cell Transplantation (methods)
  • Thalidomide (therapeutic use)
  • Transplantation, Autologous
  • Treatment Outcome
  • Vincristine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: